ArticleCell death & disease2019
Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4
Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Microchimerism: The Hidden Cellular Dialogue Between Mother and Fetal That Shapes Lifelong Immunity.Expert reviews in molecular medicine · 2026Review
- Pregnancy Outcomes After in Utero Exposure to Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2026Review
- Blockade of Tim-3 pathway in a mouse model of Toxoplasmosis: impact on brain leukocyte infiltration, parasite burden, and neuroinflammation.Scientific reports · 2026Article
- Dysfunctional decidual CD2Frontiers in immunology · 2026Article
- Inhibitory immune checkpoints in preeclampsia: current landscape, mechanisms, and clinical perspectives.Frontiers in immunology · 2026Review
- Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma.Frontiers in immunology · 2026Article
- Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.EClinicalMedicine · 2025Article
- Melanoma in Women of Reproductive Age: From Awareness and Prevention to Pregnancy-Associated Management.Cancers · 2025Review
- Dysfunctional Decidual CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immune checkpoint for pregnancy.Seminars in immunopathology · 2025Review
- Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding.International journal of biological sciences · 2025Review
- Comparison of Immune Checkpoint Molecule Expression in Different Years of House Dust Mite Subcutaneous Immunotherapy on CD4Balkan medical journal · 2024Article
- Paradoxical expression of NRP1 in decidual stromal and immune cells reveals a novel inflammation balancing mechanism during early pregnancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Tim-3 Coordinates Macrophage-Trophoblast Crosstalk via Angiogenic Growth Factors to Promote Pregnancy Maintenance.International journal of molecular sciences · 2023Article
- Regulatory T cell adoptive transfer alters uterine immune populations, increasing a novel MHC-IIFrontiers in immunology · 2023Article
- Energy metabolism and maternal-fetal tolerance working in decidualization.Frontiers in immunology · 2023Review
- Tim-3 downregulation by Toxoplasma gondii infection contributes to decidual dendritic cell dysfunction.Parasites & vectors · 2022Article
- Tim-3Cell death & disease · 2022Article
- The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia-A Narrative Review.Medicina (Kaunas, Lithuania) · 2022Review
- Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The single and/or combination use of immune checkpoint blockade therapies in human infectious diseases and cancer are rapidly expanding. Despite early efforts, substantial uncertainty remains about the safety and efficacy of immune checkpoint blockade in some populations. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin mucin-3 (Tim-3) are the major targetable co-inhibitory receptors on T cells. Here we showed that in animal studies, treatment with either CTLA-4- or Tim-3-blocking antibody caused greater susceptibility to fetal loss with altered cytokine profiles by decidual CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.